Mission Boost Grants support independent investigators' cancer research that reduces risks before human testing and advances new drugs, devices, procedures, and prevention interventions into patient studies.
Funder: American Cancer Society
Due Dates: December 1, 2026 (December cycle) | June 1, 2027 (June cycle)
Funding Amounts: Stage I: up to $297,000 total over 2 years | Stage II: up to $545,000 direct costs plus 10% allowable indirect costs over 18 months
Summary: Supports innovative, clinical-enabling cancer research that reduces risks before human testing and advances interventions into cancer patient studies.
Key Information: Stage II requires at least 18 months of Stage I funding and completion of Stage I milestones.
The American Cancer Society’s Mission Boost Grants provide independent investigators at any career stage with additional resources to translate cancer research toward human testing. Administered through Extramural Discovery Science, the program supports innovative projects with a specific path toward studying a new drug, device, or procedure in patients, rather than research without that translational focus.
Stage I supports preclinical or clinical work built around outcome-specific, unequivocal milestones that reduce the risks of patient testing. Stage II supports testing in humans after those milestones are completed. Relevant work includes first-time-in-human treatment studies, clinical proof-of-concept and side-effect reduction, clinical validation of diagnostics, prognostics and medical devices, and prevention interventions addressing cancer incidence or recurrence. ACS encourages collaborations with pharmaceutical companies and private entities to help realize a project.